PRME (Prime Medicine) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Prime Medicine's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

PRME vs IMMX, SGP, ACRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Prime Medicine's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Margin of Safety % (DCF Earnings Based) falls into.


PRME
25GF Score
Prime Medicine Inc PRME
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price